Wire · opportunities
Replimune secures FDA approval for melanoma therapy Tudriqev after long regulatory battle
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 7 August 2026 · Fusion42 review
Replimune secured FDA accelerated approval for its melanoma therapy Tudriqev in combination with Opdivo after overcoming two prior rejections and significant regulatory scrutiny. The approval is based on phase 1/2 trial data showing notable response rates in advanced melanoma patients resistant to prior PD-1 therapy.
This Wire brief sits within Fusion42's coverage of Biotech, and 14 sources have reported it between 6 Aug 2026 and 10 Aug 2026.
◆ ◆ The Wire takeaway
You face a clearer path into the US melanoma treatment market as Replimune’s FDA win opens regulatory doors for novel combination immunotherapies despite earlier setbacks. Your development and commercial plans must account for accelerated approval’s confirmatory trial demands and infrastructure rebuilding needs.
◆ Coverage
14 sources · first reported 6 Aug 2026 · latest 10 Aug 2026
◆ Related on Wire
◆ Topics